Please assess the completion status of the following clinical trial:

Trial Title: Sorafenib With Irinotecan in Metastatic Colorectal Cancer (mCRC) and K-RAS Mutation

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Age \> 18~* Written informed consent~* Histologically proven adenocarcinoma of the colon or rectum asymptomatic primary tumour or surgically removed mCRC patients with previously unresectable metastatic disease~* Patient with at least one tumoral lesion: measurable in a unidimensional way with a spiral scanner according to RECIST, no previous irradiation in this area~* Disease progression after irinotecan-based chemotherapy~* Disease progression after one or more previous lines of chemotherapy received in metastatic situation~* WHO \<= 2~* Patient having a mutated KRAS on 12 or 13 codons on the primary tumour or a metastasis~* Adequate liver function : Bilirubin ≤ 1,5 x UNL, ASAT ou ALAT ≤ 2,5 x UNL (or \< 5 x UNL for subjects having a hepatic insufficiency in connection with hepatic metastases)~* Polynuclear neutrophils ≥ 1 500/mm3~* Haemoglobin \> 10g/dl~* Platelets ≥ 100 000/mm3~* Amylase and lipase \< 1,5 x UNL~* Serum Creatinin \< 1,5 x UNL~* Adapted contraceptive measures during treatment and continued at least three months after end of the treatment~* Life expectancy \> 3 months~* Affiliated to or benefiting from health insurance~Exclusion Criteria:~* Gilbert's disease~* Brain metastases or carcinomatous symptomatic meningitis~* Exclusive bone metastasis~* Previous cancers not considered as cured in the 5 years before inclusion (except for baso-cellular skin carcinoma) Surgery (except diagnostic biopsy) or radiotherapy within 4 weeks before inclusion~* Disorders of the cardiac rhythm requiring an anti-asynchronous treatment (except beta blockers or digoxine within the framework of a chronic auricular fibrillation), unstable coronaropathy or myocardial infarction \< 6 months, congestive cardiac failure \> Rank II NYHA (Grade 2), uncontrolled arterial hypertension~* Previous epilepsy crises requiring long term antiepileptic treatment Previous organ transplant requiring immunosuppressor treatment Severe bacterial or fungus infection (\> Grade 2 NCI CTC version 3) Known HIV Infection~* Long term treatment by known inductors of the CYP 3A4 like Rifampicin, Millepertuis (hypericum perforatum), Phenytoin, Carbamazepin, Phenobarbital, Dexamethasone et Ketonazole~* Known allergy to one of the therapeutic agents~* Reasons (psychological, family, social or geographical) that could compromise the participation of the patient in the study~* Intestinal malabsorption or gastro-intestinal surgery being able to affect Sorafenib absorption. Occlusive or sub-occlusive syndrome.~* Dysphagic patient or patient not being able to take treatment by orally inflammatory~* Chronic digestive disease involving chronic diarrhoea (NCI N+Bethesda \>= 1.2g)~* Participation in another clinical trial within 30 days before the start of this study~* Other concomitant experimental drugs or other concomitant anticancer agents (except Irinotecan and Sorafenib)~* Medical or psychological state that in the opinion of the investigator will not allow the patient to terminate the study or to understand and sign the informed consent form~* Pregnancy and breast-feeding

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Sorafenib and irinotecan (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).